PepVault
/ database / Myostatin Inhibitor

ACE-031

Also: Ramatercept

Clinical-grade myostatin pathway inhibitor — terminated in muscle dystrophy trials.

Evidence
emerging
Legal status
research only
Half-life
~10-15 days
Routes
subq
View on Limitless LifeAdd to compare
What it is

ACE-031 (Acceleron) was a soluble activin receptor IIB tested in Duchenne muscular dystrophy. Trials were halted due to nosebleeds and telangiectasias, but the muscle-growth effect was robust.

Mechanism

Soluble activin receptor type IIB decoy — sponges up myostatin.

Outcomes it's matched to
Safety

Vascular side effects (nosebleeds, gum bleeding) led to trial halts.

  • Bleeding disorders
  • Pregnancy
Legal context

Research use only. Clinical development discontinued.

1:1 GUIDANCE

Have questions about this peptide?

Get free 1:1 guidance from a peptide professional before you start. They'll help you think through dosing, stacking, and whether this fits your goals.

REQUEST A CALL →
PepVault

An outcome-driven reference for modern peptides. Educational only — not medical advice, not a sales platform, not affiliated with any clinic.

Disclaimer: PepVault is an educational resource. Nothing on this site is medical advice. Many peptides discussed are research compounds and are not approved by the FDA or equivalent agencies. Always consult a qualified clinician before starting any protocol.

© 2026 PepVault